Catalyst sub-licensee DyDo launches FIRDAPSE in Japan for LEMS

CATALYST PHARMACEUTICALS, INC.

DyDo Pharma launched FIRDAPSE (amifampridine) 10 mg tablets in Japan for Lambert-Eaton myasthenic syndrome (LEMS).
FIRDAPSE is the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients 6 years and older.
Previously approved in U.S., Europe, and Canada; Japan launch expands geographic footprint.
Catalyst CEO Richard Daly cited commitment to health equity and increasing patient access worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.